The absence of an effective treatment against the coronavirus infection has led clinicians to redirect drugs that are known to be effective for other medical conditions to the treatment of COVID-19. Key among these repurposed therapeutic agents are the antimalarial drug chloroquine (CQ) and its analogue hydroxychloroquine (HCQ), which is used for the treatment of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.
Praised as a potential miracle cure,hundreds of trials got initiated across the globe for HCQ. Scientists started trying the drugs in low and high doses; alone or combined with other drugs in patients with mild or severe disease.
But this hope recently got struck by a big blow when a study came along claiming that these antimalarial drugs not only look ineffective, but are downright deadly. This study, published on May 22 in the elite journal The Lancet, was conducted by three researchers- Dr Mandeep R Mehra from Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, US; Frank Ruschitzka from university Heart Center, University Hospital Zurich, Switzerland; and Dr Amit N Patel from Department of Biomedical Engineering, University of Utah, Salt Lake City, US.
They used hospital records procured by an American healthcare analytics company Surgisphere Corporation, established in 2008 by an Indian Sapan Desai, for their study. According to their findings, COVID-19 patients taking CQ or HCQ were associated with an increase in the risk of ventricular arrhythmias and a greater hazard for in-hospital death with COVID-19. The study concluded that these drug regimens should not be used outside of clinical trials and urgent confirmation from randomised clinical trials is needed.
This story is from the July 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the July 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
